在瘤微环境中的血管原和抗血管原剂方面的进展
1Department of Pharmacy, Shaoxing People's Hospital, Shaoxing, China.
Frontiers in oncology
|December 4, 2024
概括
瘤的生长和扩散取决于血管生成,这是抗血管生成疗法 (AAT) 针对的过程. 本综述探讨了血管生成机制,当前和新型AAT药物,以及用于改善抗瘤治疗的组合疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤的发展和转移严重依赖于血管生成,即新血管的形成.
- 瘤缺氧诱导了关键血管生成因子的产生,如血管内皮生长因子 (VEGF),纤维细胞生长因子 (FGF),血小板衍生生长因子 (PDGF) 和转化生长因子-α (TGF-α).
- 这些因素刺激内皮细胞激活,促进血管生成,支持瘤生长.
研究的目的:
- 审查瘤微环境中的血管生成的分子机制.
- 讨论传统抗血管生成药物 (AAT) 和它们的局限性.
- 检查新型抗血管新生药物和组合治疗对癌症治疗的好处.
主要方法:
- 对推动瘤血管生成的分子机制的文献综述.
- 对已知抗血管原性疗法及其临床疗效的分析.
- 探索新兴的抗血管原剂和组合治疗策略.
主要成果:
- 血管新生是一个复杂的过程,涉及多个信号通路,对瘤生存和生长至关重要.
- 传统的AAT已经显示出有效性,但面临诸如耐药性和不完全血管正常化等局限性.
- 新型的AAT和组合疗法通过准多个途径,有可能增强抗瘤效果.
结论:
- 了解瘤血管生成的分子复杂性对于开发有效疗法至关重要.
- 抗血管原药开发的进展,包括组合策略,有望克服治疗挑战.
- 未来的研究应该专注于改进AAT以改善患者的治疗结果和打击瘤耐药性.
更多相关视频
09:03Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
Published on: June 30, 2023
856
09:42Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
Published on: June 26, 2019
8.7K
相关概念视频
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
01:10Mechanism of Angiogenesis
5.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K